Skip to main content

Table 1 Baseline characteristics of the study populations

From: Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project

  Population-based cohorts Disease cohorts
Number of cohorts, n 20 3
Number of subjects, n 75,367 4982
Men, n (%) 38,350 (50.9%) 3766 (75.6%)
Age at baseline, years
 Median (Q1, Q3) 50.0 (41.0, 59.0) 63.0 (54.0, 69.0)
 Proportion ≥ 65 years 13.1% 42.6%
Daily smokers, n (%) 24,077 (31.9%) 892 (17.9%)
Diabetes, n (%) 3286 (4.4%) 930 (18.7%)
Hypertension, n (%) 30,811 (40.9%) 3514 (70.5%)
Body mass index (kg/m2), mean (SD) 26.9 (4.6) 27.6 (4.1)
Total cholesterol (mmol/L)* 5.7 (5.0, 6.5) 4.9 (4.1, 5.7)
CRP (mg/L)* 1.3 (0.6, 2.9) 1.5 (0.4, 5.1)
Nt-proBNP (pg/mL)* 45.9 (24.2, 86.3) 308.0 (116.0, 803.0)
Troponin I (ng/L)* 2.3 (1.4, 3.7) 10.4 (4.6, 29.7)
eGFR (mL/min/1.73m2)*
 CKD-EPIcrea 97.6 (85.9, 107.6) 82.7 (68.7, 94.6)
 CKD-EPIcysC 92.5 (76.4, 111.5) 91.1 (69.1, 116.2)
CKD stage 3+, n (%)
 CKD-EPIcrea 2450 (3.3%) 691 (13.9%)
 CKD-EPIcysC 5562 (7.4%) 719 (14.4%)
Endpoints (n, incidence rate per 1000 person years (95% CI))
 Cardiovascular disease 6850, 8.2 (95% CI 8.0–8.4) 371, 21.2 (95% CI 19.2–23.5)
 Cardiovascular mortality 3796, 4.2 (95% CI 4.1–4.3) 132, 6.9 (95% CI 5.8–8.2)
 Total mortality 9840, 10.9 (95% CI 10.6–11.1) 343, 17.9 (95% CI 16.1–19.9)
  1. *Median (interquartile range, Q1, Q3)